IndraLab

Statements


MDM2-R175H inhibits TP53. 1 / 1
| 1

reach
"Thus, inhibition of RhoA activity through inhibition of the mevalonate-RhoA axis by an HMG-CoA-R inhibitor (cerivastatin) or an inhibitor of geranylgeranyltransferase type I (GGTI-298) reduces HDAC6 activity and hence induces hyperacetylation of HSP90, leading to dissociation of mutp53 from HSP90 and degradation of mutp53 by MDM2 (R175H, L194F, M237I, R249S, R273H)."